Actionable news
All posts from Actionable news
Actionable news in RPRX: Repros Therapeutics Inc.,

Oculus Innovative Sciences Receives European Approval to Market Sinudox™ Indicated for Use in Nasal Irrigation

PETALUMA, Calif., April 13, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (OCLS) (OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the issuance of a new CE Mark in Europe for Microcyn®-based Sinudox™ solution, a formulation intended for nasal irrigation including the moistening of cuts, abrasions and lacerations located in the nasal cavity.

Lori Smith, senior vice president of marketing and sales for Oculus said, “We are pleased that the European regulatory agency recognizes our Microcyn-based Sinudox as sufficiently safe to be used on mucous membranes in the nasal cavity. Each year, hundreds of thousands of people undergo surgery of the nose for cosmetic purposes as well as for common intranasal surgeries, including chronic sinusitis, septoplasty, turbinate reductions and the removal of nasal polyps. We believe Sinudox can be an important new product for healthcare professionals in both the cosmetic and traditional nasal surgery settings.”

Oculus is currently in discussions with potential European partners for the distribution of Sinudox in Europe.

About Chronic Sinusitis
Chronic sinusitis is a common disease worldwide, particularly in places with high levels of atmospheric pollution. In the Northern Hemisphere, damp temperate climates along with higher concentrations of pollens are associated with a higher prevalence of chronic sinusitis.

Chronic sinusitis is one of the more prevalent chronic illnesses in the United States, affecting persons of all age groups. The overall prevalence of CRS in the United States is 146 per 1000...